# Ampersand Biomedicines

> Ampersand Biomedicines is a Boston-area biotech founded by Flagship Pioneering that builds programmable biologic medicines designed to act only where disease lives. Its computational Address, Navigate, Determine (AND) Platform maps the body for ideal localization targets and designs AND-Body Therapeutics that anchor at a disease site and conditionally switch on biology there, aiming to widen the therapeutic window and cut the off-tissue side effects that limit conventional drugs.

- **Founded:** 2020
- **Headquarters:** Boston, United States
- **Founders:** Noubar Afeyan (Co-Founder, Chairman (Flagship Pioneering Founder & CEO)), Avak Kahvejian (Co-Founder, Board Chair (General Partner, Flagship Pioneering)), Raffi Afeyan (Co-Founder), Yann Echelard (Co-Founder), Charlotte Nicod (Co-Founder), Nick Plugis (Co-Founder)
- **Team size:** ~73 employees
- **Products:** AND Platform (Address, Navigate, Determine), AND-Body Therapeutics, Address Map
- **Notable:** Raised $65M Series B in March 2025 with Eli Lilly as a strategic investor, Total funding of roughly $115M since launch, Advanced two lead programs (immuno-inflammation and immuno-oncology) toward IND-enabling studies in 2025

## Products & services

- **AND Platform (Address, Navigate, Determine)** — A computationally powered platform that uses multi-omics analysis to identify ideal 'addresses' for drug localization across organs, cells and diseases, then informs the design of localizing biologics.
- **AND-Body Therapeutics** — Multi-specific, modular biologic medicines that pair a localizing element (to anchor in diseased tissue) with an actuator (to conditionally switch on therapeutic biology only at the disease site).
- **Address Map** — A proprietary tool for identifying optimal localizing targets for specific organs, cells and diseases.

## Achievements

- Raised $65M Series B in March 2025 with Eli Lilly as a strategic investor
- Total funding of roughly $115M since launch
- Advanced two lead programs (immuno-inflammation and immuno-oncology) toward IND-enabling studies in 2025
- Established discovery partnerships with Pfizer, Pioneering Medicines and Genethon
- Built a novel computational AND Platform to program biologics by location

## Latest updates

- **2025-03** — Closed $65M Series B led by Flagship with Eli Lilly; announced two lead programs advancing to IND-enabling studies and a second obesity discovery partnership.
- **2023-03** — Publicly unveiled by Flagship Pioneering with $50M, introducing the AND Platform and AND-Body Therapeutics.

## Links

- Website: https://ampersand.bio
- LinkedIn: https://www.linkedin.com/company/ampersand-biomedicines
- Twitter/X: https://twitter.com/AmpersandBio

---

Profile page: https://yespress.io/ampersand-biomedicines
Published by YesPress — https://yespress.io
Last updated: 2026-06-10